Works matching DE "IMATINIB"

Results: 3251

Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience.

Published in:

Indian Journal of Pharmacology, 2022, v. 54, n. 5, p. 349, doi. 10.4103/ijp.ijp_844_21

By:

Swain, Trupti;
Goutam, Siddhartha;
Jena, Rabindra;
Rout, Niranjan

Publication type:

Article

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.

Published in:

Indian Journal of Pharmacology, 2016, v. 48, n. 4, p. 458, doi. 10.4103/0253-7613.186214

By:

Singh, Surjit;
Sharma, Pramod Kumar

Publication type:

Article

Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female.

Published in:

2015

By:

Agrawal, Prabhat;
Singh, Omkar;
Nigam, Ashwini Kumar;
Upadhyay, Shalini

Publication type:

Case Study

Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female.

Published in:

Indian Journal of Pharmacology, 2015, v. 47, n. 6, p. 685, doi. 10.4103/0253-7613.169576

By:

Agrawal, Prabhat;
Singh, Omkar;
Nigam, Ashwini Kumar;
Upadhyay, Shalini

Publication type:

Article

A rare case of imatinib-induced erythroderma.

Published in:

2013

By:

Verma, Rajesh;
Vasudevan, Biju;
Pragasam, Vijendran;
Neema, Shekhar

Publication type:

Case Study

Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice.

Published in:

Indian Journal of Pharmacology, 2011, v. 43, n. 4, p. 389, doi. 10.4103/0253-7613.83107

By:

Prasad, A. M.;
Ramnarayan, K.;
Nalini, K.;
Bairy, K. L.

Publication type:

Article

Reduced exposure of imatinib after coadministration with acetaminophen in mice.

Published in:

Indian Journal of Pharmacology, 2009, v. 41, n. 4, p. 167, doi. 10.4103/0253-7613.56071

By:

Nassar, Inthisham;
Pasupati, Thanikachalam;
Judson, John Paul;
Segarra, Ignacio

Publication type:

Article

Hematological and nonhematological toxicities of imatinib mesylate in patients with chronic myeloid leukemia and gastrointestinal stromal tumor.

Published in:

Indian Journal of Pharmacology, 2007, v. 39, n. 4, p. 192

By:

Usman, Mohammad;
Syed, Naveen Naz;
Kakepoto, Ghulam Nabi;
Adil, Salman Naseem;
Khurshid, Mohammad

Publication type:

Article

Imatinib mesylate-induced generalized hypopigmentation in patients with chronic myeloid leukemia.

Published in:

Indian Journal of Pharmacology, 2006, v. 38, n. 1, p. 66

By:

Gupta, D. K.;
Saluja, S.;
Bhasin, S.;
Sharma, M.

Publication type:

Article

Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.

Published in:

Modern Pathology, 2004, v. 17, n. 8, p. 946, doi. 10.1038/modpathol.3800144

By:

Rassidakis, George Z.;
Georgakis, Georgios V.;
Oyarzo, Mauricio;
Younes, Anas;
Medeiros, L. Jeffrey

Publication type:

Article

Synthesis of Complex and Diverse Compounds through Ring Distortion of Abietic Acid.

Published in:

Angewandte Chemie, 2014, v. 126, n. 1, p. 224, doi. 10.1002/ange.201308743

By:

Rafferty, Ryan J.;
Hicklin, Robert W.;
Maloof, Katherine A.;
Hergenrother, Paul J.

Publication type:

Article

Minimal change glomerulopathy in a cat

Published in:

Journal of Feline Medicine & Surgery, 2011, v. 13, n. 4, p. 291, doi. 10.1016/j.jfms.2010.12.011

By:

Backlund, Brianna;
Cianciolo, Rachel E.;
Cook, Audrey K.;
Clubb, Fred J.;
Lees, George E.

Publication type:

Article

Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.

Published in:

2005

By:

Stroszczynski, Christian;
Jost, Dominik;
Reichardt, Peter;
Chmelik, Petra;
Gaffke, Gunnar;
Kretzschmar, Albrecht;
Schneider, Ulrike;
Felix, Roland;
Hohenberger, Peter

Publication type:

journal article

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues.

Published in:

Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 3, p. 697, doi. 10.1007/s00280-011-1746-1

By:

Haglund, Caroline;
Åleskog, Anna;
Nygren, Peter;
Gullbo, Joachim;
Höglund, Martin;
Wickström, Malin;
Larsson, Rolf;
Lindhagen, Elin

Publication type:

Article

Imatinib mesylate in thymic epithelial malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 2, p. 309, doi. 10.1007/s00280-011-1690-0

By:

Palmieri, Giovannella;
Marino, Mirella;
Buonerba, Carlo;
Federico, Piera;
Conti, Salvatore;
Milella, Michele;
Petillo, Luigi;
Evoli, Amelia;
Lalle, Maurizio;
Ceribelli, Anna;
Merola, Gerardina;
Matano, Elide;
Sioletic, Stefano;
Placido, Sabino;
Di Lorenzo, Giuseppe;
Damiano, Vincenzo

Publication type:

Article

A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 3, p. 643, doi. 10.1007/s00280-010-1530-7

By:

Hebb, Jonathan;
Assouline, Sarit;
Rousseau, Caroline;
DesJardins, Pierre;
Caplan, Stephen;
Egorin, Merrill;
Amrein, Lilian;
Aloyz, Raquel;
Panasci, Lawrence

Publication type:

Article

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 2, p. 285, doi. 10.1007/s00280-010-1479-6

By:

Kim, Kyu-pyo;
Ryu, Min-Hee;
Yoo, Changhoon;
Ryoo, Baek-Yeol;
Choi, Dae;
Chang, Heung;
Lee, Jae-Lyun;
Beck, Mo;
Kim, Tae;
Kang, Yoon-Koo

Publication type:

Article

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 1, p. 69, doi. 10.1007/s00280-010-1431-9

By:

Benjamin, Robert;
Schöffski, Patrick;
Hartmann, Jörg;
Oosterom, Allan;
Bui, Binh;
Duyster, Justus;
Schuetze, Scott;
Blay, Jean-Yves;
Reichardt, Peter;
Rosen, Lee;
Skubitz, Keith;
McCoy, Sheryl;
Sun, Yu-Nien;
Stepan, Daniel;
Baker, Laurence

Publication type:

Article

Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 4, p. 919, doi. 10.1007/s00280-010-1394-x

By:

Rappa, Germana;
Anzanello, Fabio;
Lorico, Aurelio

Publication type:

Article

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.

Published in:

2011

By:

Helbig, Grzegorz;
Moskwa, Andrzej;
Hus, Marek;
Piszcz, Jarosław;
Swiderska, Alina;
Urbanowicz, Alina;
Całbecka, Małgorzata;
Seferyńska, Ilona;
Raźny, Małgorzata;
Rodzaj, Marek;
Żuk, Ewa;
Kyrcz-Krzemień, Sławomira

Publication type:

Letter

Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 275, doi. 10.1007/s00280-010-1315-z

By:

Pinto, Ana;
Ângelo, Susana;
Moreira, João;
Simões, Sérgio

Publication type:

Article

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 1, p. 15, doi. 10.1007/s00280-010-1513-8

By:

Wang, Wei-Lien;
Conley, Anthony;
Reynoso, David;
Nolden, Laura;
Lazar, Alexander;
George, Suzanne;
Trent, Jonathan

Publication type:

Article

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 1, p. 25, doi. 10.1007/s00280-010-1526-3

By:

Gounder, Mrinal;
Maki, Robert

Publication type:

Article

The role of imatinib plasma level testing in gastrointestinal stromal tumor.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 1, p. 45, doi. 10.1007/s00280-010-1527-2

By:

George, Suzanne;
Trent, Jonathan

Publication type:

Article

Preface.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 1, p. 1, doi. 10.1007/s00280-010-1511-x

By:

Patel, Shreyaskumar

Publication type:

Article

Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 2, p. 255, doi. 10.1007/s00280-009-1158-7

By:

Radujkovic, Aleksandar;
Fruehauf, Stefan;
Zeller, W. Jens;
Anthony D. Ho Ho;
Topaly, Julian

Publication type:

Article

LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 6, p. 1039, doi. 10.1007/s00280-009-1109-3

By:

Mencalha, Andre Luiz;
Du Rocher, B.;
Salles, D.;
Binato, R.;
Abdelhay, E.

Publication type:

Article

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 5, p. 961, doi. 10.1007/s00280-009-1103-9

By:

Sawaki, Akira;
Yamada, Yasuhide;
Komatsu, Yoshito;
Kanda, Tatsuo;
Doi, Toshihiko;
Koseki, Masato;
Baba, Hideo;
Sun, Yu-Nien;
Murakami, Koji;
Nishida, Toshirou

Publication type:

Article

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 1, p. 195, doi. 10.1007/s00280-008-0905-5

By:

Breccia, Massimo;
Frustaci, Anna Maria;
Cannella, Laura;
Soverini, Simona;
Stefanizzi, Caterina;
Federico, Vincenzo;
Grammatico, Sara;
Santopietro, Michelina;
Alimena, Giuliana

Publication type:

Article

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1161, doi. 10.1007/s00280-008-0858-8

By:

Breccia, Massimo;
Cilloni, Daniela;
Cannella, Laura;
Stefanizzi, Caterina;
Tafuri, Agostino;
Fama, Angelo;
Santopietro, Michelina;
Saglio, Giuseppe;
Alimena, Giuliana

Publication type:

Article

Effect of antacid on imatinib absorption.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 525, doi. 10.1007/s00280-008-0778-7

By:

Sparano, Brian A.;
Egorin, Merrill J.;
Parise, Robert A.;
Walters, Jennifer;
Komazec, Kristin A.;
Redner, Robert L.;
Beumer, Jan H.

Publication type:

Article

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 2, p. 229, doi. 10.1007/s00280-008-0730-x

By:

Menon-Andersen, Divya;
Mondick, John T.;
Jayaraman, Bhuvana;
Thompson, Patrick A.;
Blaney, Susan M.;
Bernstein, Mark;
Bond, Mason;
Champagne, Martin;
Fossler, Michael J.;
Barrett, Jeffrey S.

Publication type:

Article

Imatinib inhibition of fludarabine uptake in T-lymphocytes.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 4, p. 735, doi. 10.1007/s00280-007-0629-y

By:

Woodahl, Erica;
Wang, Joanne;
Heimfeld, Shelly;
Ren, Aaron;
McCune, Jeannine

Publication type:

Article

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 61, n. 4, p. 713, doi. 10.1007/s00280-007-0507-7

By:

Vigna, Ernesto;
Lucia, Eugenio;
Gentile, Massimo;
Mazzone, Carla;
Bisconte, Maria;
Gentile, Carlo;
Armentano, Antonio;
Ottaviani, Emanuela;
Rondoni, Michela;
Martinelli, Giovanni;
Morabito, Fortunato

Publication type:

Article

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 61, n. 3, p. 515, doi. 10.1007/s00280-007-0498-4

By:

Britten, Carolyn D.;
Kabbinavar, Fairooz;
Hecht, J. Randolph;
Bello, Carlo L.;
Li, Jim;
Baum, Charles;
Slamon, Dennis

Publication type:

Article

Trichosanthin down-regulated p210<sup>Bcr-Abl</sup> and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.

Published in:

Cancer Chemotherapy & Pharmacology, 2007, v. 60, n. 4, p. 581, doi. 10.1007/s00280-007-0457-0

By:

Zhang, Kunzhong;
Xu, Jianhua;
Huang, Xiuwang;
Wu, Lixian;
Wen, Caixia;
Hu, Yingying;
Su, Yu;
Chen, Yuanzhong;
Zhang, Zhiqiang

Publication type:

Article

The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.

Published in:

Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 6, p. 855, doi. 10.1007/s00280-006-0334-2

By:

Oostendorp, Roos L.;
Marchetti, Serena;
Beijnen, Jos H.;
Mazzanti, R.;
Schellens, Jan H. M.

Publication type:

Article

cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib.

Published in:

Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 3, p. 349, doi. 10.1007/s00280-006-0276-8

By:

Bianchini, Michele;
Martinelli, Giovanni;
Renzulli, Matteo;
Gonzalez Cid, Marcela;
Larripa, Irene

Publication type:

Article

Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.

Published in:

Cancer Chemotherapy & Pharmacology, 2006, v. 58, n. 5, p. 716, doi. 10.1007/s00280-005-0181-6

By:

Froehner, Michael;
Beuthien-Baumann, Bettina;
Dittert, Dag-Daniel;
Schuler, Ulrich;
Wirth, Manfred P.

Publication type:

Article

Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.

Published in:

Cancer Chemotherapy & Pharmacology, 2005, v. 56, n. 4, p. 358, doi. 10.1007/s00280-005-1031-2

By:

Pappas, Periklis;
Karavasilis, Vasilis;
Briasoulis, Evangelos;
Pavlidis, Nicholas;
Marselos, Marios

Publication type:

Article

Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.

Published in:

2005

By:

O'Reilly, T.;
Wartmann, M.;
Maira, S.-M.;
Hattenberger, M.;
Vaxelaire, J.;
Muller, M.;
Ferretti, S.;
Buchdunger, E.;
Altmann, K.-H.;
McSheehy, P.M.J.

Publication type:

journal article

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.

Published in:

2005

By:

Judson, Ian;
Peiming Ma;
Bin Peng;
Verweij, Jaap;
Racine, Amy;
Paola, Eugenio;
Glabbeke, Martine;
Dimitrijevic, Sasa;
Scurr, Michelle;
Dumez, Herlinde;
Oosterom, Allan;
Ma, Peiming;
Peng, Bin;
di Paola, Eugenio Donato;
van Glabbeke, Martine;
van Oosterom, Allan

Publication type:

journal article

Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.

Published in:

2004

By:

Katayama, Rieko;
Huelsmeyer, Michael K.;
Marr, Amanda K.;
Kurzman, Ilene D.;
Thamm, Douglas H.;
Vail, David M.

Publication type:

journal article

Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.

Published in:

Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 5, p. 433, doi. 10.1007/s00280-003-0756-z

By:

Nikolova, Zariana;
Peng, Bin;
Hubert, Martine;
Seiberling, Michael;
Keller, Urs;
Ho, Yu-Yun;
Schran, Horst;
Capdeville, Renaud

Publication type:

Article

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

Published in:

Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 4, p. 313, doi. 10.1007/s00280-003-0741-6

By:

le Coutre, Philipp;
Kreuzer, Karl-Anton;
Pursche, Stefan;
v. Bonin, Malte;
Leopold, Traugott;
Baskaynak, Gökben;
Dörken, Bernd;
Ehninger, Gerhard;
Ottmann, Oliver;
Jenke, Andreas;
Bornhäuser, Martin;
Schleyer, Eberhard

Publication type:

Article

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.

Published in:

Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 2, p. 102, doi. 10.1007/s00280-003-0722-9

By:

Bolton, Ann E.;
Peng, Bin;
Hubert, Martine;
Krebs-Brown, Axel;
Capdeville, Renaud;
Keller, Urs;
Seiberling, Michael

Publication type:

Article

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.

Published in:

2003

By:

Tsimberidou, Apostolia M.;
Colburn, Dawn E.;
Welch, Mary Alma;
Cortes, Jorge E.;
Verstovsek, Srdan;
O'Brien, Susan M.;
Albitar, Maher;
Kantarjian, Hagop M.;
Giles, Francis J.

Publication type:

journal article

c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).

Published in:

Cancer Chemotherapy & Pharmacology, 2002, v. 50, n. 2, p. 167, doi. 10.1007/s00280-002-0477-8

By:

Hotfilder, Marc;
Lanvers, Claudia;
Jürgens, Heribert;
Boos, Joachim;
Vormoor, Josef

Publication type:

Article

TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.

Published in:

Amino Acids, 2013, v. 44, n. 2, p. 461, doi. 10.1007/s00726-012-1354-3

By:

Huang, Zheng-Lan;
Gao, Miao;
Ji, Mao-Sheng;
Tao, Kun;
Xiao, Qing;
Zhong, Liang;
Zeng, Jian-Ming;
Feng, Wen-Li

Publication type:

Article

Optimal Use of Targeted Agents for Advanced Gastrointestinal Stromal Tumours.

Published in:

Oncology, 2010, v. 78, n. 2, p. 130, doi. 10.1159/000312655

By:

Reichardt, Peter

Publication type:

Article